Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.59 |
| ▸ | NPY1R | P25929 | 9/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.59 |
| ▸ | NPY2R | P49146 | 5/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29461973 | 0.92 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29540421 | 0.92 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29794240 | 0.89 | NPY4R (0.59) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30603887 | 0.89 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL30844091 | 0.88 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29630454 | 0.88 | NPY4R (0.62) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29973536 | 0.87 | NPY4R (0.63) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL8927815 | 0.87 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL8927814 | 0.87 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30592732 | 0.87 | NPY4R (0.61) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | NPY4R 4433/4885NPY1R 3079/4885NPY5R 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.